Related Experiment Video
Updated: Jan 13, 2026
A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Fewer Admissions, Shorter Stays: Phenobarbital Use for Alcohol Withdrawal in the Emergency Department
Blake Briggs1, Logan Smith2, Noah Yates3
1Division of Emergency Medicine, University of Tennessee Health Science Center Knoxville, Knoxville, Tennessee, USA.
Background:
Alcohol withdrawal syndrome (AWS) significantly contributes to ED resource utilization. While phenobarbital is increasingly used as an alternative to benzodiazepines, data comparing their impact on ED utilization remain limited. We evaluated whether phenobarbital monotherapy improves ED operational outcomes compared to benzodiazepines or combination therapy.
Methods:
We conducted a single-center, retrospective cohort study of 1178 adults at a regional academic medical center from January 1, 2020, to December 31, 2023. Patients ≥ 18 years old who were treated with intravenous (IV) phenobarbital, IV benzodiazepines, or both for AWS in the ED were included. The primary outcome was hospital admission. Secondary outcomes included ED length of stay, return visits within 72 h of index visit, and 30-day hospital readmission. A formalized data abstraction process was utilized. Analyses used chi-squared or Kruskal-Wallis tests and logistic regression to estimate odds ratios with 95% confidence intervals.
Results:
Of 777 eligible encounters, 459 (59.1%) resulted in admission. Admission rates were 74.0% for benzodiazepine-only encounters, followed by combination therapy (62.4%), and lowest for phenobarbital-only (52.1%; OR 0.44, 95% CI 0.30-0.66, p < 0.0001). Among discharged patients (318 encounters), median ED LOS was shortest in the phenobarbital-only group (5.8 h), versus 7.6 h for benzodiazepine-only and 10.3 h for combination therapy (p < 0.0001). Logistic regression analysis revealed treatment with phenobarbital alone was independently associated with discharge, while increasing age, increasing heart rate, and treatment with benzodiazepines alone were independently associated with hospitalization.
Conclusions:
Phenobarbital monotherapy for AWS was associated with lower admission rates, shorter ED LOS, and fewer IV medication administrations compared to benzodiazepine-based regimens. Return visit rates were similar across all groups. These findings are exploratory, underscoring the need for prospective studies to confirm these associations.
More Related Videos
15:27Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
Published on: July 13, 2014
05:12Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
Published on: June 23, 2023
Related Concept Videos
01:20Sedatives and Hypnotics Drugs: Barbiturates
01:14CNS Depressants: Barbiturates and Benzodiazepines
01:24Parenteral Anesthetics: Overview
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:28Depressants
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...